Ciproxin licensed for UTI in children

The licence for Ciproxin (ciprofloxacin) has been extended to include the second- and third-line treatment of complicated UTIs and pyelonephritis in children and adolescents aged between 1-17 years.

The dose is 10-20mg/kg orally every 12 hours up to a maximum of 750mg per dose. The recommended duration of treatment is 10-21 days.

View Ciproxin drug record

Further information: Bayer plc

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

Cases of necrotising fasciitis of the genitalia or...

New advice for carbimazole over malformation and pancreatitis risks

New advice for carbimazole over malformation and pancreatitis risks

Reports of congenital malformations and acute pancreatitis...

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Antibiotic Treatments in Adults, Summary of Regimens

Antibiotic Treatments in Adults, Summary of Regimens

Dose regimens for common bacterial infections.